TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02267785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skill-Based Exercise
Description: The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
Study: NCT03375307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study: NCT02267785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Contact
Description: The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
Study: NCT02504892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is a commercial agent and is supplied by Novartis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is a commercial agent and is supplied by Novartis.
Study: NCT04036136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Treatment will consist of 15 weekly 45-minute sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Treatment
Description: Treatment will consist of 15 weekly 45-minute sessions.
Study: NCT01276847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing \> 100 kg on Day 1, and Weeks 4 and 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
Study: NCT00453388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT02433158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
Study: NCT03608423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive endoscopy-guided surgery
Description: Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
Study: NCT03548571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell immunization
Description: Intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant temozolomide
Description: After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
Study: NCT02523040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT03441074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced olfactory stimuli
Description: Patients in intervention group will get enhanced olfactory stimuli during perioperative period (2 to 3 days before the surgery and 7 days after the surgery), by using portable scented sachets.
Study: NCT04542499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Study: NCT02918890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced Movement Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-arm Bimanual Intensive Therapy
Study: NCT04451135

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalographic (EEG)
Description: EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Closed loop acoustic stimulation (CLAS)
Description: Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
Study: NCT03375307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT04451135

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)
Description: The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ictal Electroencephalographic (EEG) Measurements
Description: A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-Ictal Electroencephalographic (EEG) Suppression Measurements
Description: A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Measurements of Sleep Microstructure
Description: Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
Study: NCT03375307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT02441699

Intervention type: BEHAVIORAL
Intervention: Improved water supply and sanitation
Description: Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
Study: NCT02813824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid lysinate 300 mg
Description: Daily dose during 4 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Aspirin 300)
Description: Daily dose during 4 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid lysinate 100 mg
Description: Daily dose during 4 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 100 (for Aspirin 100)
Description: Daily dose during 4 years
Study: NCT03423953

Intervention type: DEVICE
Intervention: Comprehensive Nano
Description: Patients requiring the Comprehensive Nano shoulder system.
Study: NCT03935854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF, Ketogenic Diet
Description: Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
Study: NCT00798070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dtEC→dtT
Description: Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC→T
Description: Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
Study: NCT04138030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Endoscopic Mucosal Resection
Description: Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Snare Endoscopic Mucosal Resection
Description: Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
Study: NCT00554580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status.
Study: NCT04717063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peroxyl Oral Product
Description: mouth wash

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo mouth wash
Study: NCT00039182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00779038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl ITS
Description: 40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
Study: NCT04976075

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT00554580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care of acute pulmonary oedema
Description: Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min.
Study: NCT01571609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer
Description: FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer
Description: FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes.
Study: NCT01099007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Person
Description: Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At Home
Description: Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
Study: NCT03911115

Intervention type: OTHER
Intervention: Food preference questionnaire
Description: This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
Study: NCT03506594

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency non ablative
Description: The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
Study: NCT00241111

Intervention type: DRUG
Group type: OTHER
Intervention: zoledronic acid
Study: NCT01696877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix acetate
Description: Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
Study: NCT02425475

Intervention type: DEVICE
Intervention: LIMES
Description: All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
Study: NCT00776100

Intervention type: OTHER
Group type: OTHER
Intervention: clinical observation
Description: Patients undergo observation for 6 weeks.
Study: NCT01696877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix acetate
Description: Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
Study: NCT00776100

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 days a week for 6 weeks.
Study: NCT01696877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
Study: NCT00927628

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were \>40-years-of-age.
Study: NCT01857323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax®
Description: Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
Study: NCT02465333

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Heel Fat Grafting
Description: Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Heel Fat Grafting
Description: Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity.
Study: NCT01140022

Intervention type: OTHER
Intervention: CT Screening
Description: Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
Study: NCT03208309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo